Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) and Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) are two firms in the Biotechnology that compete against each other. Below is a comparison of their risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals Inc.	N/A	0.00	48.36M	-1.97	0.00
Pieris Pharmaceuticals Inc.	42.34M	3.82	7.58M	-0.13	0.00

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 provides us the net margins, return on assets and return on equity of both businesses.

	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals Inc.	0.00%	-41.3%	-38%
Pieris Pharmaceuticals Inc.	-17.90%	-18.1%	-5.1%

Liquidity

The Current Ratio and Quick Ratio of Corvus Pharmaceuticals Inc. are 16.1 and 16.1 respectively. Its competitor Pieris Pharmaceuticals Inc.’s Current Ratio is 3.6 and its Quick Ratio is 3.6. Corvus Pharmaceuticals Inc. can pay off short and long-term obligations better than Pieris Pharmaceuticals Inc.

Institutional and Insider Ownership

Institutional investors owned 87.6% of Corvus Pharmaceuticals Inc. shares and 66.9% of Pieris Pharmaceuticals Inc. shares. Insiders owned roughly 5.08% of Corvus Pharmaceuticals Inc.’s shares. Comparatively, insiders own roughly 0.21% of Pieris Pharmaceuticals Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Corvus Pharmaceuticals Inc.	-2.68%	-26.33%	-45.35%	-54.81%	-45.51%	-43.82%
Pieris Pharmaceuticals Inc.	1.77%	-8.97%	-34.91%	-40.82%	-43.81%	-54.3%

For the past year Corvus Pharmaceuticals Inc.’s stock price has smaller decline than Pieris Pharmaceuticals Inc.

Summary

Pieris Pharmaceuticals Inc. beats Corvus Pharmaceuticals Inc. on 6 of the 9 factors.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint. The company is also developing an anti-CD73 monoclonal antibody that inhibits the production of adenosine; an antagonist of the adenosine A2B receptor; and small molecule covalent inhibitors of interleukin-2 inducible kinase. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.

Pieris Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers and develops Anticalin-based drugs. It develops Anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. The company primarily focuses on the development of four drug candidates, including PRS-080 designed to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis; PRS-060, a drug candidate that binds to the IL-4RA receptor alpha-chain, which is used for the treatment of asthma and other inflammatory diseases; PRS-343, a bispecific protein for oncology diseases; and PRS-332, a bispecific anticalin-antibody fusion protein for oncology diseases. It has strategic partnership agreements with Allergan, Inc.; Sanofi Group; Daiichi Sankyo Company Limited; F.Hoffmann- La Roche Ltd. and Hoffmann- La Roche Inc.; ASKA Pharmaceutical Co., Ltd; and Les Laboratoires Servier and Institut de Recherches Internationales. The company also has a research and licensing agreement with Technische Universität München; and a collaboration agreement with AstraZeneca. Pieris Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.